Stevens Capital Management LP Makes New Investment in Pfizer Inc. $PFE

Stevens Capital Management LP acquired a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 193,796 shares of the biopharmaceutical company’s stock, valued at approximately $4,938,000.

Other institutional investors also recently modified their holdings of the company. Peak Asset Management LLC boosted its position in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares during the last quarter. Community Bank & Trust Waco Texas boosted its position in Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 412 shares during the period. Able Wealth Management LLC grew its stake in Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 413 shares during the last quarter. CVA Family Office LLC grew its position in shares of Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 413 shares during the last quarter. Finally, Boltwood Capital Management increased its position in Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 420 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $27.84.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive BREAKWATER trial results announced — clinical readout may bolster confidence in Pfizer’s pipeline and future revenue opportunities. Pfizer Inc (PFE) announces positive results from BREAKWATER trial
• Positive Sentiment: Erste Group slightly raised FY2026 and FY2027 EPS forecasts (to $2.97 and $2.84, respectively) — incremental analyst upgrades signal modestly improved earnings visibility, though changes are tiny versus consensus.
• Positive Sentiment: Oncology sales growth and pipeline positioning — Pfizer reported oncology revenue gains and cites Padcev, Lorbrena and new launches offsetting older product declines, supporting medium‑term top‑line growth. Pfizer targets long-term oncology growth amid competitive pressure
• Positive Sentiment: Appears on lists for high dividend, low‑volatility stocks — income investors may find Pfizer’s yield and lower beta attractive in defensive allocations. 10 High Dividend Stocks With Low Volatility
• Neutral Sentiment: Stock discussed in bullish retail/investor commentary — several opinion pieces argue Pfizer could be an underrated or buy‑and‑hold healthcare play, but these are narrative‑driven and not primary catalysts. Is Pfizer Stock an Underrated Healthcare Investment Play?
• Neutral Sentiment: Peer comparison: AstraZeneca highlighted as having stronger growth targets — competitive context may temper upside expectations even if Pfizer remains cheaper on valuation. AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
• Negative Sentiment: Barclays initiated coverage with an UNDERWEIGHT — a high‑profile sell/underweight call can trigger short‑term selling and weigh on institutional demand. Barclays initiates coverage of Pfizer (PFE) with underweight recommendation
• Negative Sentiment: Additional bearish analyst initiations and commentary — Benzinga and other outlets reported bearish starts from some analysts, increasing near‑term downside risk from flows and sentiment. This Pfizer Analyst Begins Coverage On A Bearish Note
• Negative Sentiment: Yield concerns and income‑investor risk narratives — pieces highlighting a ~6% yield frame the payout as potentially risky if earnings or cash flow weaken, which can pressure the stock in rate‑sensitive markets. Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Pfizer Trading Down 0.8%

NYSE PFE opened at $26.66 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market cap of $151.55 billion, a P/E ratio of 19.60 and a beta of 0.47. The stock’s 50-day moving average is $25.95 and its 200-day moving average is $25.31. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.63 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s payout ratio is presently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.